海正药业 HISUN Pharmaceuticals   
 始创于1956年的浙江海正药业股份有限公司（股票代码600267，以下简称“海正药业”）秉承“执著药物创新，成就健康梦想”的使命和“成为广受尊重的全球化制药企业”的愿景，致力于整合药物研发与生产资源，为全球客户提供更好的产品和服务，通过美国FDA、欧盟EDQM、澳大利亚TGA、韩国KFDA等官方认证的品种达到40多个，销往全球30多个国家和地区。
2009年，公司荣获“全国五一劳动奖状”，海正、HISUN及图形被认定为“中国驰名商标”，入选“中国万种微生物基因组计划”和“国家重大（磅）级药物品种产业化技术创新联盟”。因圆满完成“抗甲流药物中间体生产”的国家任务，受到省政府的通令嘉奖。
2010年，公司入选浙江省医药工业“十强企业”，并荣获“国内最佳产品线十佳工业企业” 称号，同时被誉为“金蜜蜂奖成长型企业”。



Founded in 1956, the mission for Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267) hereinafter called "HISUN") is one of "To be persistent in pharmaceutical innovation for humans' well-being". The company's vision is to become "a widely respected global pharmaceutical provider".It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services.To date, over 40 of the company's products have passed certification by the FDA (U.S.),EDQM (EU) ,TGA (Australia) ,KFDA(Korea), etc.,and are sold to more than 30 countries worldwide.

Over the years, HISUN has received numerous commendations and accolades. For example, in 2009 the company received the "May 1st Labor Award". The company's name in Chinese and English (HISUN) and its logo were recognized as "Famous Brands in China". The company was also selected to participate in "China's Genome Project for 10,000 Micro-organisms" and "National Technical Innovation Alliance for Commercialization of Major Pharmaceuticals". As a result of its successful completion of the Central Government's assignment with respect to the production of "anti-H1N1 pharmaceutical intermediate agents", the company was commended by the Zhejiang Provincial Government.

In 2010, Hisun was selected as the "Top 10 Enterprises " of ZheJiang Medicine Industry, and honored as the "Top 10 Industrial Enterprises of Optimum Product Lines in China ", and at the same time, Hisun awarded the "Gold Bee Prize of Growing Enterprise". At the same year, Hisun achived sales revenue of RMB 4.5 billion, total profit of RMB 450 million, which were 14.4% and 28.2% respectively higher than the previous year.